A former ai regulator, now working in industry, has expressed a view that the biopharma sector is misinterpreting guidance from the fda. This perspective suggests a potential discrepancy between the fda's intentions and the industry's understanding of the guidance. The nature and implications of this perceived misinterpretation are not specified.